Preventive Migraine Medications Explained

There are two fundamentally different approaches to treating migraine with medication. The first is acute treatment, medication taken during an attack to reduce its severity and duration. The second is preventive treatment, medication taken regularly whether or not an attack is occurring, with the goal of reducing how often attacks happen, how severe they are, and how well they respond to acute treatment when they do occur.

Most people with migraine are familiar with acute treatment. Fewer are aware that preventive treatment exists, that it is recommended for a substantial portion of the migraine population, and that it is dramatically underutilized. Research from the American Migraine Prevalence and Prevention Study found that fewer than thirteen percent of people who met criteria for preventive treatment were receiving it at the time of the survey.

Understanding what preventive treatment is, who should consider it, and what options exist is essential information for anyone whose migraine is not adequately controlled with acute treatment alone.

Who Should Consider Preventive Treatment

The American Headache Society and the American Academy of Neurology have published guidelines identifying the circumstances under which preventive migraine treatment should be considered. These include migraine attacks occurring on four or more days per month, attacks that are severely disabling even when infrequent, attacks that do not respond adequately to acute treatment, overuse of acute medications creating risk of medication overuse headache, specific migraine subtypes including hemiplegic migraine and migraine with brainstem aura, and patient preference for reducing attack frequency rather than relying solely on acute treatment.

The threshold of four or more migraine days per month is widely cited as a starting point for discussing prevention, though individual circumstances matter. The functional impact, not just the frequency, informs the decision.

How Preventive Medications Work

Preventive migraine medications do not work the same way for everyone, and the mechanism by which any given medication prevents migraine is not always fully understood. The general principle is that these medications reduce the neurological excitability of the migraine brain over time, raising the threshold at which triggers can initiate an attack.

Preventive medications typically require several weeks to months of consistent use before their full effect is apparent. This is one of the most common reasons preventive treatment fails in practice. People who discontinue a medication after two or three weeks because they do not see immediate results may be stopping before the medication has had time to work. Most preventive medications require a trial of at least eight to twelve weeks at an adequate dose before efficacy can be properly assessed.

Established Oral Preventive Medications

Several classes of oral medication have established evidence for migraine prevention and have been used in clinical practice for decades.

Beta blockers, particularly propranolol and metoprolol, have some of the longest track records in migraine prevention. They were originally developed for cardiovascular indications and were found to reduce migraine frequency as a secondary effect. They are generally well tolerated but are contraindicated in people with asthma, certain cardiac conditions, and some other medical circumstances.

Tricyclic antidepressants, particularly amitriptyline and nortriptyline, have evidence for migraine prevention at doses lower than those used for depression. They are often used when migraine coexists with sleep disturbance, anxiety, or depression, as they address multiple symptoms simultaneously. Common side effects include sedation, dry mouth, and weight gain.

Anticonvulsant medications, particularly topiramate and valproate, have strong evidence for migraine prevention. Topiramate is one of the most commonly prescribed preventive medications for migraine and has been shown in multiple large clinical trials to reduce monthly migraine days significantly. Side effects can include cognitive effects, weight loss, and tingling in the extremities. Valproate is effective but requires monitoring for liver function and is contraindicated in pregnancy due to teratogenic risk.

CGRP-Targeted Preventive Medications

The development of medications targeting calcitonin gene-related peptide (CGRP) represents the most significant advance in migraine prevention in decades. CGRP plays a central role in migraine pathophysiology, and blocking its activity reduces attack frequency with a specificity that older preventive medications do not achieve.

Anti-CGRP monoclonal antibodies, including erenumab, fremanezumab, galcanezumab, and eptinezumab, are administered by injection or infusion on a monthly or quarterly basis. They were developed specifically for migraine prevention and have demonstrated meaningful reductions in monthly migraine days in large clinical trials. They are generally well tolerated, with injection site reactions being the most common side effect.

CGRP receptor antagonists, the gepant class of medications, include atogepant and rimegepant in their oral preventive formulations. These offer a daily oral option for people who prefer not to use injectable medications.

Onabotulinumtoxin A

Onabotulinumtoxin A, commonly known as Botox, is approved specifically for the prevention of chronic migraine in adults. It is administered by a clinician as a series of injections around the head and neck every twelve weeks. Multiple large clinical trials have demonstrated its efficacy in reducing monthly headache days in people with chronic migraine. It is not approved for episodic migraine.

Choosing a Preventive Medication

The choice of preventive medication is individualized and involves consideration of the migraine pattern, comorbid conditions, contraindications, side effect profile, patient preference, and practical factors including cost and administration route. A person with migraine and hypertension may find a beta blocker addresses both conditions. A person with migraine and anxiety may do well with an antidepressant. A person with chronic migraine who has not responded to oral medications may be a candidate for Botox or a CGRP monoclonal antibody.

The conversation about preventive treatment is one that every person with frequent or disabling migraine deserves to have with a clinician who understands the current treatment landscape.